Drug Information Association Pharmacovigilance and Risk Management Strategies 2017: Overview of the Generic Drug Program and Surveillance.

Autor: Chazin HD; 1 U.S. Food and Drug Administration, Office of Generic Drugs, Silver Spring, MD, USA., Peters JR; 1 U.S. Food and Drug Administration, Office of Generic Drugs, Silver Spring, MD, USA., Catterson DM; 1 U.S. Food and Drug Administration, Office of Generic Drugs, Silver Spring, MD, USA., Osterhout JL; 1 U.S. Food and Drug Administration, Office of Generic Drugs, Silver Spring, MD, USA., Forsyth LM; 1 U.S. Food and Drug Administration, Office of Generic Drugs, Silver Spring, MD, USA., Lee JE; 1 U.S. Food and Drug Administration, Office of Generic Drugs, Silver Spring, MD, USA., Kim EK; 1 U.S. Food and Drug Administration, Office of Generic Drugs, Silver Spring, MD, USA., Feibus KB; 1 U.S. Food and Drug Administration, Office of Generic Drugs, Silver Spring, MD, USA.

Publikováno v: Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2019 Mar; Vol. 53 (2), pp. 249-253. Date of Electronic Publication: 2018 May 09.